Mark X. Sliwkowski

31.9k citations

111 papers · 21.9k indexed · 12 hit papers · h-index 52

Impact in

Oncology top 0.05%
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
Radiology, Nuclear Medicine and Imaging top 0.02%
- Monoclonal and Polyclonal Antibodies Research

Papers in

Radiology, Nuclear Medicine and Imaging 76
- Monoclonal and Polyclonal Antibodies Research 71
- Radiopharmaceutical Chemistry and Applications 8
Oncology 86
- HER2/EGFR in Cancer Research 82
- Peptidase Inhibition and Analysis 10

Co-authors: Yosef Yarden Charles Eigenbrot Robert W. Akita Gail D. Lewis Phillips Jennifer L. Stamos Kathryn L. Parsons Ira Mellman Daniel J. Leahy
Journals: Cancer Research (14 papers)Journal of Biological Chemistry (12 papers)Journal of Clinical Oncology (7 papers)Clinical Cancer Research (5 papers)Oncogene (4 papers)
Partner nations: United States France United Kingdom

In The Last Decade

Mark X. Sliwkowski

111 papers receiving 21.3k citations

Hit Papers

12 papers align trajectories log scale

Antibody Therapeutics in Cancer 2013 · 446 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2013 Science
2011 Nature Reviews Clinical Oncology
2009 Cancer Cell
2008 Cancer Research
2008 Cancer Research
2004 Cancer Cell
2003 Molecular Cell
2002 Journal of Biological Chemistry
2001 Nature Reviews Molecular Cell Biology
1999 Oncogene
1994 Journal of Biological Chemistry
1992 Science

Peers

Countries citing papers authored by Mark X. Sliwkowski

Since Specialization

Citations

This map shows the geographic impact of Mark X. Sliwkowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark X. Sliwkowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark X. Sliwkowski more than expected).

Fields of papers citing papers by Mark X. Sliwkowski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark X. Sliwkowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark X. Sliwkowski. The network helps show where Mark X. Sliwkowski may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark X. Sliwkowski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark X. Sliwkowski Line = papers co-authored together Mark X. Sliwkowski links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody–Drug Conjugates Cancer Research ·Tran Cao Quy, Josefa Chuh, Yong Ma, Donglu Zhang, Katherine R. Kozak, Yichin Liu, Thomas H. Pillow, Jack Sadowsky, Tommy K. Cheung, Qui Phung, Benjamin Haley, Eric Schnieders, Robert W. Akita, Mark X. Sliwkowski, Andrew G. Polson	2017	98
2	Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers Molecular Cancer Therapeutics ·Chunrong Li, Shyhmin Huang, Eric A. Armstrong, David M. Francis, Lauryn R. Werner, Mark X. Sliwkowski, Albert van der Kogel, Paul M. Harari	2015	26
3	Afucosylated Antibodies Increase Activation of FcγRIIIa-Dependent Signaling Components to Intensify Processes Promoting ADCC Cancer Immunology Research ·Scot D. Liu, Cécile Chalouni, Judy Young, Teemu T. Junttila, Mark X. Sliwkowski, John B. Lowe	2014	51
4	Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy Clinical Cancer Research ·Gail D. Lewis Phillips, Carter T. Fields, Guangmin Li, Donald Dowbenko, Gabriele Schaefer, Kathy D. Miller, Fabrice André, Howard A. Burris, Kathy S. Albain, Nadia Harbeck, Véronique Dièras, Diana Crivellari, Fang Ting Liang, Ellie Guardino, Steven R. Olsen, Lisa Crocker, Mark X. Sliwkowski	2013	148
5	Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation Cancer Research ·Shyhmin Huang, Chunrong Li, Eric A. Armstrong, Chimera R. Peet, Jarob Saker, Lukas C. Amler, Mark X. Sliwkowski, Paul M. Harari	2012	150
6	Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer Breast Cancer Research and Treatment ·Teemu T. Junttila, Guangmin Li, Kathryn L. Parsons, Gail D. Lewis Phillips, Mark X. Sliwkowski	2010	411
7	Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Clinical Cancer Research ·Jagath R. Junutula, Kelly M. Flagella, Richard Graham, Kathryn L. Parsons, А.В. Дзубан, Helga Raab, Sunil Bhakta, Trung Van Nguyen, Debra L. Dugger, Guangmin Li, Elaine Mai, Gail D. Lewis Phillips, Hajime Hiraragi, Reina N. Fuji, Jay Tibbitts, Richard Vandlen, Susan D. Spencer, Richard H. Scheller, Paul Polakis, Mark X. Sliwkowski	2010	214
8	Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 Cancer Cell ·Teemu T. Junttila, Robert W. Akita, Kathryn L. Parsons, Carter T. Fields, Gail D. Lewis Phillips, Lori S. Friedman, Deepak Sampath, Mark X. Sliwkowski Hit paper breakdown →	2009	651
9	Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab Clinical Cancer Research ·Evelyn Yao, Wei Zhou, Si Tuen Lee-Hoeflich, Tom Truong, Peter M. Haverty, Jeffrey Eastham‐Anderson, Nicholas Lewin‐Koh, Bert Gunter, Marcia Belvin, Lesley Murray, Lori S. Friedman, Mark X. Sliwkowski, Klaus P. Hoeflich	2009	104
10	A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy Cancer Research ·Si Tuen Lee-Hoeflich, Lisa Crocker, Evelyn Yao, Thinh Q. Pham, Xander Munroe, Klaus P. Hoeflich, Mark X. Sliwkowski, Howard M. Stern Hit paper breakdown →	2008	501
11	Trastuzumab-MC-vc-PAB-MMAF: The effects of the Drug:Antibody Ratio (DAR) on efficacy, toxicity and pharmacokinetics. Cancer Research ·Douglas D. Leipold, Nelson L. ‘Shasha’ Jumbe, Debra L. Dugger, Lisa Crocker, R G Finucane, Mark X. Sliwkowski, Damon L. Meyer, Peter D. Senter, Jay Tibbitts	2007	3
12	Evolution of the MDA-MB-175 breast cancer cell line from a low to a high HER2 expressing tumor line Cancer Research ·Lisa Crocker, Gail D. Lewis Phillips, Brian Reardon, Hartmut Koeppen, Mark X. Sliwkowski, Ralph Schwall, Sarajane Ross	2005	1
13	Blockade of Epidermal Growth Factor- or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 Has Divergent Downstream Signaling and Growth Effects Cancer Research ·James G. Jackson, Patricia St. Clair, Mark X. Sliwkowski, Michael G. Brattain	2004	83
14	Ready to partner Nature Structural & Molecular Biology ·Mark X. Sliwkowski	2003	30
15	Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth Gastroenterology ·Ping Wen Kuohung, Hongmiao Sheng, Jinyi Shao, Christopher S. Williams, Raymond N. DuBois, Paul I. Pisacane, Mark X. Sliwkowski	2001	149
16	Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. PubMed ·Hirokazu Kurokawa, Anne E.G. Lenferink, Jean F. Simpson, Paul I. Pisacane, Mark X. Sliwkowski, James T. Forbes, Carlos L. Arteaga	2000	310
17	A potential role for activated HER-2 in prostate cancer. PubMed ·David B. Agus, Robert W. Akita, William D. Fox, Julie A. Lofgren, Brian Higgins, Noboru Sekiya, Howard I. Scher, Mark X. Sliwkowski	2000	36
18	A Discrete Three-amino Acid Segment (LVI) at the C-terminal End of Kinase-impaired ErbB3 Is Required for Transactivation of ErbB2 Journal of Biological Chemistry ·Gabriele Schaefer, Robert W. Akita, Mark X. Sliwkowski	1999	30
19	Analysis of Heregulin-Induced ErbB2 Phosphorylation with a High-Throughput Kinase Receptor Activation Enzyme-Linked Immunosorbant Assay Analytical Biochemistry ·M D Sadick, Mark X. Sliwkowski, Andrew Nuijens, Laura Bald, Nan Chiang, Julie A. Lofgren, Wai Lee Wong	1996	21
20	Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. PubMed ·Michael F. Press, Malcolm C. Pike, Secília Rodrigues Rosa, Giun‐Yi Hung, John P. Meredith, Elif Birlikbaş, J Danyluk, William Godolphin, Mark X. Sliwkowski, Robert W. Akita	1993	351

About Mark X. Sliwkowski

Mark X. Sliwkowski is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology, Immunology and Allergy, Biochemistry and Molecular Biology, having authored 111 papers that have together received 21.9k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (82 papers), Monoclonal and Polyclonal Antibodies Research (71 papers), Glycosylation and Glycoproteins Research (16 papers), Lung Cancer Treatments and Mutations (11 papers), Peptidase Inhibition and Analysis (10 papers), Radiopharmaceutical Chemistry and Applications (8 papers), Cell Adhesion Molecules Research (7 papers) and Selenium in Biological Systems (6 papers). The work is most often cited by research in Oncology (14.5k citations), Radiology, Nuclear Medicine and Imaging (9.8k citations), Immunology and Allergy (1.2k citations), Molecular Biology (9.9k citations) and Pulmonary and Respiratory Medicine (3.4k citations). Mark X. Sliwkowski has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Yosef Yarden, Charles Eigenbrot, Robert W. Akita, Gail D. Lewis Phillips, Jennifer L. Stamos, Kathryn L. Parsons, Ira Mellman, Daniel J. Leahy, Lisa Crocker and Guangmin Li. Their work appears in journals such as Cancer Research, Journal of Biological Chemistry, Journal of Clinical Oncology, Clinical Cancer Research and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact